Table 3 Key performance indicators (invitation, participation, recall and cancer detection) of the Population-based Mammographic Screening Programme, Flanders Belgium 2002–2016
From: Flemish breast cancer screening programme: 15 years of key performance indicators (2002–2016)
Performance indicator [EU desirable target] | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | AAPC all years | APCb last segment | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | (95% CI) | Yeara | % | (95% CI) | ||||||||||||||||
Target population 01/01, N | 692,964 | 699,472 | 707,645 | 717,956 | 728,628 | 739,449 | 751,171 | 763,832 | 778,866 | 799,767 | 816,921 | 830,455 | 843,110 | 854,612 | 861,223 | |||||
BC or Bilateral mastectomy, N | 13,569 | 15,886 | 18,248 | 19,989 | 20,833 | 21,689 | 22,522 | 22,985 | 23,400 | 23,935 | 24,680 | 25,220 | 25,810 | 26,226 | 26,474 | |||||
Eligible - refuses to be invited, N | 12,364 | 13,693 | 14,998 | 16,264 | 17,481 | 18,702 | 19,757 | 21,001 | 21,991 | 23,089 | 23,863 | 24,625 | 24,962 | 25,223 | 24,809 | |||||
Eligible - not to be invited this yearb, N | 45,207 | 171,528 | 198,729 | 227,791 | 255,135 | 314,695 | 279,757 | 333,516 | 335,365 | 360,949 | 371,003 | 370,777 | 380,358 | 386,578 | 390,457 | |||||
Eligible - to be invited this year, N | 621,824 | 498,365 | 475,670 | 453,912 | 435,179 | 384,363 | 429,135 | 386,330 | 398,110 | 391,794 | 397,375 | 409,833 | 411,980 | 416,585 | 419,483 | |||||
Invitations sent (invitation coverage), % | 22.0 | 33.1 | 41.5 | 50.4 | 68.0 | 68.9 | 76.1 | 85.0 | 88.9 | 93.2 | 93.1 | 94.0 | 95.1 | 95.7 | 96.0 | + 10.5b | (+ 8.3; + 12.8) | 2011 | + 0.4 | (−2.8; + 3.8) |
Eligible population 01/01, N | 679,395 | 683,586 | 689,397 | 697,967 | 707,795 | 717,760 | 728,649 | 740,847 | 755,466 | 775,832 | 792,241 | 805,235 | 817,300 | 828,386 | 834,749 | |||||
PMSP coverage, % | 17.9 | 24.8 | 30.9 | 35.0 | 39.4 | 43.1 | 44.0 | 45.4 | 45.8 | 47.4 | 48.4 | 48.4 | 48.3 | 48.9 | 50.0 | + 7.5b | (+ 6.5; + 8.6) | 2007 | + 1.6b | (+ 1.1; + 2.0) |
Opportunistic coverage, % | unknown | 21.3 | 20.5 | 20.2 | 20.3 | 19.9 | 19.2 | 18.3 | 17.7 | 17.2 | 16.8 | 16.0 | 15.3 | 14.8 | 14.1 | −3.0b | (−3.3; −2.6) | 2007 | −3.6b | (−3.3; −2.6) |
No coverage, % | 53.8 | 48.6 | 44.7 | 40.4 | 37.0 | 36.8 | 36.4 | 36.6 | 35.3 | 34.8 | 35.6 | 36.3 | 36.3 | 35.8 | −3.0b | (−3.5; −2.5) | 2012 | + 0.7 | (−0.4; + 1.8) | |
All invitations sent, N | 120,517 | 164,296 | 202,155 | 241,076 | 311,940 | 276,511 | 339,264 | 343,924 | 370,439 | 382,475 | 385,966 | 402,569 | 407,864 | 415,304 | 417,493 | |||||
Invitation Response Rate, % | 50.9 | 57.8 | 50.3 | 48.3 | 48.0 | 54.8 | 49.1 | 51.1 | 48.0 | 51.3 | 50.1 | 51.2 | 49.3 | 51.7 | 49.8 | −0.3 | (−0.9; + 0.4) | |||
All PMSP examinations, N | 103,909 | 119,861 | 127,714 | 134,772 | 164,075 | 165,873 | 176,133 | 183,175 | 183,810 | 203,326 | 199,899 | 209,809 | 204,540 | 218,723 | 218,118 | |||||
With BCR link, % | 80.0 | 83.3 | 98.7 | 98.9 | 98.6 | 98.9 | 98.7 | 98.9 | 99.0 | 99.4 | 99.4 | 99.5 | 99.6 | 99.7 | 99.8 | |||||
PMSP examinations with BCR link, N | 83,100 | 99,787 | 126,007 | 133,265 | 161,777 | 164,129 | 173,768 | 181,082 | 181,968 | 202,101 | 198,747 | 208,839 | 203,735 | 218,155 | 217,614 | |||||
mean age, years | 59.8 | 58.6 | 58.8 | 58.9 | 58.4 | 58.7 | 58.4 | 58.5 | 58.5 | 58.6 | 58.6 | 58.7 | 58.6 | 58.8 | 58.8 | |||||
initial screening, N | 83,100 | 89,385 | 62,149 | 46,728 | 55,899 | 44,823 | 40,562 | 42,923 | 38,995 | 40,506 | 40,961 | 36,852 | 37,497 | 38,454 | 38,851 | |||||
mean age, years | 59.8 | 58.4 | 56.2 | 57.1 | 55 | 54.7 | 54.2 | 53.5 | 53.5 | 53.2 | 53 | 52.7 | 52.7 | 52.6 | 52.8 | |||||
subsequent irregular screening, N | 12 | 16,138 | 15,935 | 21,479 | 19,179 | 15,886 | 16,714 | 17,911 | 18,950 | 17,676 | 17,207 | 16,863 | 19,490 | 21,045 | ||||||
mean age, years | 58.9 | 61.2 | 60.3 | 60.3 | 60.5 | 60.6 | 60.7 | 60.3 | 60.6 | 60.8 | 60.7 | 60.7 | 60.8 | 60.8 | ||||||
subsequent regular screening, N | 10,390 | 47,720 | 70,602 | 84,399 | 100,127 | 117,320 | 121,445 | 125,062 | 142,645 | 140,110 | 154,780 | 149,375 | 160,211 | 157,718 | ||||||
mean age, years | 60.1 | 61.2 | 59.8 | 60.2 | 60.2 | 59.6 | 59.9 | 59.8 | 59.8 | 60 | 60 | 59.9 | 60 | 60 | ||||||
Digital screening, % | 0.0 | 0.0 | 0.1 | 0.3 | 1.9 | 9.0 | 21.4 | 45.6 | 59.6 | 79.5 | 88.7 | 95.3 | 95.2 | 96.8 | 98.9 | |||||
Women recalled for diagnostic assessment, N | 4377 | 5598 | 5774 | 5859 | 7488 | 6322 | 7567 | 6706 | 6038 | 5932 | 6066 | 5328 | 5232 | 5183 | 5585 | |||||
Recall Rate, % | 5.3 | 5.6 | 4.6 | 4.4 | 4.6 | 3.9 | 4.4 | 3.7 | 3.3 | 2.9 | 3.1 | 2.6 | 2.6 | 2.4 | 2.6 | |||||
initial screens, % [< 5%] | 5.3 | 5.8 | 6 | 6.1 | 6.8 | 6.4 | 7.5 | 6.4 | 5.5 | 5.3 | 5.4 | 4.4 | 4.5 | 4.5 | 4.7 | −1.5b | (−2.9; −0.1) | 2008 | −5.1 b | (−6.9; −3.3) |
subsequent irregular screens, % | 3.6 | 4.6 | 4.5 | 4.1 | 4.9 | 4.2 | 3.8 | 3.1 | 3.8 | 3.2 | 3.4 | 3.2 | 3.4 | −2.9b | (−4.6; −1.1) | |||||
subsequent regular screens, % [< 3%] | 3.6 | 3.1 | 3.2 | 3.2 | 2.7 | 3.2 | 2.7 | 2.6 | 2.2 | 2.3 | 2 | 2 | 1.8 | 1.9 | −5.0b | (−6.0; − 3.9) | ||||
Screen detected cancers, N | 797 | 894 | 789 | 856 | 967 | 888 | 952 | 976 | 1018 | 1126 | 1153 | 1227 | 1123 | 1195 | 1190 | |||||
Cancer Detection Rate, ‰ | 9.6 | 9.0 | 6.3 | 6.4 | 6.0 | 5.4 | 5.5 | 5.4 | 5.6 | 5.6 | 5.8 | 5.9 | 5.5 | 5.5 | 5.5 | |||||
initial screens, ‰ | 9.6 | 9.2 | 7.2 | 8.0 | 7.4 | 6.6 | 7.1 | 6.5 | 6.3 | 6.5 | 6.3 | 5.8 | 5.6 | 6.4 | 6.3 | −0.6 | (−1.4; + 0.2) | |||
subsequent irregular screens, ‰ | 6.7 | 7.1 | 6.4 | 6.0 | 7.4 | 8.1 | 6.9 | 7.3 | 9.1 | 8.2 | 8.2 | 9.0 | 7.5 | + 2.1b | (+ 0.3; + 3.9) | |||||
subsequent regular screens, ‰ | 6.4 | 4.9 | 5.2 | 4.9 | 4.8 | 4.7 | 4.6 | 5.2 | 5.1 | 5.2 | 5.6 | 5.2 | 4.8 | 5.0 | 0.0 | (−1.1; + 1.1) | ||||
False-Positive Recalls, N | 3582 | 4704 | 4986 | 5003 | 6521 | 5434 | 6615 | 5730 | 5020 | 4806 | 4913 | 4101 | 4109 | 3988 | 4395 | |||||
False-Positive Recall Rate, ‰ | 43.1 | 47.1 | 39.6 | 37.5 | 40.3 | 33.1 | 38.1 | 31.6 | 27.6 | 23.8 | 24.7 | 19.6 | 20.2 | 18.3 | 20.2 | |||||
initial screens, ‰ | 43.1 | 49.1 | 52.8 | 53.4 | 60.4 | 57.7 | 67.7 | 57.9 | 49.1 | 46.2 | 47.7 | 38.5 | 39.7 | 38.1 | 40.3 | −1.4 | (−3.5; + 0.8) | 2007 | −5.3 b | (−7.4; − 3.1) |
subsequent irregular screens, ‰ | 29.6 | 39.3 | 38.6 | 34.9 | 41.5 | 33.8 | 31.2 | 24.0 | 29.0 | 23.9 | 25.7 | 22.6 | 26.2 | −4.0b | (−6.1; −1.9) | |||||
subsequent regular screens, ‰ | 29.2 | 25.7 | 26.6 | 27.4 | 21.8 | 27.4 | 22.1 | 20.4 | 17.4 | 17.5 | 14.7 | 14.6 | 13.0 | 14.4 | −6.1b | (−7.4; −4.9) | ||||
Positive predictive value, % | 18.2 | 16.0 | 13.6 | 14.6 | 12.9 | 14.0 | 12.6 | 14.6 | 16.9 | 19.0 | 19.0 | 23.0 | 21.5 | 23.1 | 21.3 | |||||
initial screens, % | 18.2 | 15.8 | 12.0 | 13.0 | 10.9 | 10.2 | 9.5 | 10.2 | 11.3 | 12.3 | 11.7 | 13.1 | 12.4 | 14.4 | 13.6 | + 0.1 | (−2.5; + 2.8) | 2006 | + 3.8 b | (+ 1.5; + 6.1) |
subsequent irregular screening, % | 18.4 | 15.3 | 14.2 | 14.8 | 15.2 | 19.4 | 18.2 | 23.3 | 23.9 | 25.5 | 24.3 | 28.4 | 22.3 | + 5.0b | (+ 2.5; + 7.4) | |||||
Subsequent regular screening, % | 17.9 | 15.9 | 16.5 | 15.2 | 18.0 | 14.6 | 17.3 | 20.3 | 22.6 | 23.0 | 27.8 | 26.2 | 27.1 | 25.7 | + 3.8b | (+ 0.6; + 7.0) | 2013 | −2.1 | (−11.5; + 8.4) | |